



NEWS RELEASE

Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET

2022-10-11

DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR[®] artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, has been invited to present at the Microcap Rodeo presents The Windy City Roundup 2022 conference, which is being held live, in-person on October 12th - 13th, 2022. CEO & President, Panna Sharma will present at the conference.

Lantern Pharma is scheduled to present on Wednesday, Oct. 12th at 11:00 a.m. ET/10:00 a.m. CT. Management will be available for one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at <https://www.webcaster4.com/Webcast/Page/2924/46673>.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuereirect.com.

Investors can [register here](#).

About the MicroCap Rodeo Best Ideas Conferences:

The second-annual, live in-person MicroCap Rodeo is back. Join us as we go on the road and participate in the Windy City Roundup 2022 in Chicago, Illinois. Over two days in October, investors can harness top stocks for their

portfolios. They'll meet with executive management teams from approximately 60-plus microcap companies across a wide variety of industries and gain an understanding into the key value drivers and potential trends for 2023. Complementing the interactive, in-depth 25-minute one-on-one meeting format will be four tracks of company presentations.

About Lantern Pharma:

Lantern Pharma (NASDAQ:LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR[®] A.I. and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across nine disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes.

Contact:

Nicole Leber

Investor Relations Associate

ir@lanternpharma.com

Please find more information at:

Website: **www.lanternpharma.com**

LinkedIn: **<https://www.linkedin.com/company/lanternpharma/>**

Twitter: **[@lanternpharma](https://twitter.com/lanternpharma)**

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR[®] platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR[®] platform to streamline the drug development process; our intention to leverage artificial intelligence,

machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

SOURCE: Lantern Pharma Inc.

View source version on accesswire.com:

<https://www.accesswire.com/719947/Lantern-Pharma-to-Present-at-The-MicroCap-Rodeo-Presents-The-Windy-City-Roundup-2022-on-Wednesday-October-12-at-1100-am-ET>

Released October 11, 2022